Kymera Therapeutics, Inc. KYMR
We take great care to ensure that the data presented and summarized in this overview for Kymera Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding KYMR
View all-
Price T Rowe Associates Inc Baltimore, MD6.87MShares$235 Million0.03% of portfolio
-
Baker Bros. Advisors LP New York, NY6MShares$205 Million2.67% of portfolio
-
Bvf Inc San Francisco, CA5.16MShares$177 Million7.77% of portfolio
-
Avoro Capital Advisors LLC New York, NY5.15MShares$176 Million3.02% of portfolio
-
Atlas Venture Life Science Advisors, LLC4.9MShares$168 Million32.49% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.89MShares$167 Million0.0% of portfolio
-
Black Rock Inc. New York, NY4.16MShares$142 Million0.0% of portfolio
-
Siren, L.L.C. New York, NY2.97MShares$102 Million5.28% of portfolio
-
State Street Corp Boston, MA1.69MShares$57.9 Million0.0% of portfolio
-
Driehaus Capital Management LLC Chicago, IL1.39MShares$47.6 Million0.54% of portfolio
Latest Institutional Activity in KYMR
Top Purchases
Top Sells
About KYMR
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Insider Transactions at KYMR
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|
Apr 08
2025
|
Noah Goodman Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+49.96%
|
-
|
|
Mar 31
2025
|
Bruce N. Jacobs Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+9.93%
|
$50,000
$2.08 P/Share
|
|
Mar 03
2025
|
Jared Gollob Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
5,740
-2.3%
|
$172,200
$30.67 P/Share
|
|
Mar 03
2025
|
Jared Gollob Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+19.26%
|
-
|
|
Mar 03
2025
|
Bruce N. Jacobs Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
7,035
-1.69%
|
$211,050
$30.67 P/Share
|
|
Mar 03
2025
|
Bruce N. Jacobs Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+12.56%
|
-
|
|
Mar 03
2025
|
Jeremy G Chadwick Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
1,383
-1.0%
|
$41,490
$30.67 P/Share
|
|
Mar 03
2025
|
Jeremy G Chadwick Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+26.54%
|
-
|
|
Mar 03
2025
|
Ellen Chiniara Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
2,241
-1.37%
|
$67,230
$30.67 P/Share
|
|
Mar 03
2025
|
Ellen Chiniara Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
27,500
+25.04%
|
-
|
|
Jan 10
2025
|
Bruce N. Jacobs Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+5.29%
|
$20,000
$2.08 P/Share
|
|
Jan 10
2025
|
Nello Mainolfi Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+1.49%
|
$20,000
$2.08 P/Share
|
|
Jan 06
2025
|
Ellen Chiniara Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
3,129
-5.4%
|
$128,289
$41.75 P/Share
|
|
Dec 02
2024
|
Pamela Esposito |
SELL
Open market or private sale
|
Direct |
2,500
-100.0%
|
$122,500
$49.0 P/Share
|
|
Dec 02
2024
|
Pamela Esposito |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+50.0%
|
$72,500
$29.55 P/Share
|
|
Sep 17
2024
|
Pamela Esposito |
SELL
Open market or private sale
|
Direct |
13,500
-73.52%
|
$648,000
$48.25 P/Share
|
|
Sep 17
2024
|
Pamela Esposito |
BUY
Exercise of conversion of derivative security
|
Direct |
13,500
+38.51%
|
$283,500
$21.87 P/Share
|
|
Aug 26
2024
|
Jeffrey W. Albers |
SELL
Open market or private sale
|
Direct |
5,000
-100.0%
|
$245,000
$49.1 P/Share
|
|
Aug 26
2024
|
Jeffrey W. Albers |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+50.0%
|
$50,000
$10.34 P/Share
|
|
Aug 20
2024
|
Baker Bros. Advisors LP |
BUY
Open market or private purchase
|
Indirect |
1
|
$46
$46.41 P/Share
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 172K shares |
|---|---|
| Open market or private purchase | 1 shares |
| Grant, award, or other acquisition | 163K shares |
| Open market or private sale | 572K shares |
|---|